arrow
R

Renata de Sá Brito Fróes

Universidade Federal de Minas Gerais
H指数:6
被引数:102

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn's Disease: A Multicenter Observational Study

真实世界中,乌司木单抗相较于抗-TNF药物的作为克罗恩病的一线或二线生物制剂的疗效与安全性比较:一项多中心观察性研究

2025-12-010
PRE
Prior Exposure to Biologics and its Impact on Outcomes in Ulcerative Colitis: An Integrated Analysis of a Brazilian Cohort

既往生物制剂暴露及其对溃疡性结肠炎结局的影响:一项巴西队列的整合分析

2025-12-010
PRE
Real-World Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Retrospective Cohort Study

奥博珠单抗在溃疡性结肠炎患者中的真实世界有效性与安全性:一项回顾性队列研究

2025-10-010
OAAI
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
P1176 Low serum albumin levels are associated with higher colectomy rates in patients with moderate-to-severe ulcerative colitis on tofacitinib
2025-01-220
PRE
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024-12-010
OA
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
2024-02-211
OAAI
Clinical Profile of Patients With Inflammatory Bowel Disease in Brazil: Analysis of the National Registry (GEDIIB)
2023-12-010
OA
Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB)
2021-05-270
PRE